Physicians' Academy for Cardiovascular Education

Why focus on triglyceride-rich lipoproteins and their remnants?

10' education - Nov. 23, 2021 - Prof. Henry Ginsberg, MD - New York, NY, USA

Video navigation menu

  • Causes of residual risk for CVD 01:31
  • Role of triglycerides in residual risk of CVD 02:50
  • What are triglyceride-rich lipoproteins (TGRL) and TGRL remnants? 04:22
  • How do TGRL remnants differ from LDL and do these differences make them more atherogenic?  07:50
  • Does lowering of triglycerides prevent CVD? 13:14

Transcript

Show transcript

Educational information

This lecture by Henry Ginsberg is part of a series titled "Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunities".

This program has been designed to educate physicians and other healthcare professionals with an interest in CV risk on lipid-associated residual risk beyond LDL-c and provide an update of novel findings in basic and clinical science with regard to the association of triglyceride-rich remnant lipoproteins and CV risk. In addition, guidance will be given how to use findings from studies on triglyceride-rich lipoproteins in the treatment of patients in clinical practice.

Faculty

Prof. Henry Ginsberg, MD - Professor of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant received from Pfizer Inc.

Click here for the meeting report View slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: